In its second-quarter earnings release, Exelixis, Inc. (NASDAQ:EXEL) announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed. This study evaluates cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable soft-tissue disease who have progressed after treatment with one prior NHT. Also Read: Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study. As previously reported, the CONTACT-02 study met one of its two primary endpoints, demonstrating a statistically significant benefit in progression-free survival (PFS) (hazard ratio: 0.65; p=0.0007) in the predefined PFS intent-to-treat population (i.e., the first 400 randomized patients). While the final OS continued to favor the combination of cabozantinib and atezolizumab, it ...